| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Gillian Curran Prospect Financial Group LLC | 1,914.62 | $6,128.71 | $10,530.44 | $4,401.73 | 71.82% |
| Biotechnology Industry | Healthcare Sector | Yong Qi Quek CEO | NASDAQ (CM) Exchange | G2592E102 CUSIP |
| SG Country | 15 Employees | - Last Dividend | 27 May 2026 Last Split | - IPO Date |
Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company based in Singapore, focused on innovating products designed to manage chronic wounds effectively. The company is at the forefront of the biomedical industry, committed to the research, development, and commercialization of cutting-edge solutions. Cuprina manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the acclaimed MEDIFLY brand. These bio-dressing products are recognized as an effective biological debridement tool aimed at enhancing the healing of chronic wounds. Beyond its primary focus on wound care, Cuprina also explores opportunities in the health and beauty sectors, offering a diverse range of cosmeceutical products that aim to support overall health and aesthetic improvement.
The flagship products of Cuprina Holdings, MEDIFLY bio-dressing items utilize sterile blowfly larvae as a natural biological debridement tool. These products are specifically designed for effective wound care, promoting healing by facilitating the removal of necrotic tissue and reducing infection risks. The bio-dressing provides a moist wound environment, which is crucial for speeding up the healing process in chronic wounds.
Cuprina's venture into the health and beauty sectors is marked by its range of cosmeceutical products. These products blend cosmetic and pharmaceutical benefits to provide effective solutions for skin health and beauty. The formulations may include active ingredients aimed at delivering targeted results, such as anti-aging, hydration, and skin rejuvenation, addressing various skin concerns while enhancing overall appearance.